Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Folinic acid added to risperidone for children with autism spectrum disorder
IRCT20090117001556N114Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Autism Spectrum Disorder (ASD) comparing Folinic acid + risperidone with Risperidone control (2 arms). Primary endpoint: Severity of autism. Started Nov 2018; status: completed.
02
Drugs
folinic acidrisperidone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20090117001556N114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N114.